Key clinical point: Compared with adalimumab, both 15 mg and 30 mg upadacitinib showed similar or better efficacy through 2 years and a similar safety profile in patients with psoriatic arthritis (PsA).

Major finding: At week 104, a similar proportion of patients receiving 15/30 mg upadacitinib vs adalimumab achieved ≥20% improvement in the American College of Rheumatology criteria (69.0%/69.5% vs 63.4%), whereas significantly more patients receiving 30 mg upadacitinib vs adalimumab achieved minimal disease activity (45.9% vs 37.8%; P < .05). The safety profiles of upadacitinib and adalimumab were comparable.

Study details: Findings are from an exploratory analysis of the SELECT-PsA 1 study including 1704 patients with active PsA and inadequate response/intolerance to ≥1 non-biologic disease-modifying antirheumatic drug who were randomly assigned to receive upadacitinib (15 or 30 mg) or adalimumab.

Disclosures: This study was funded by AbbVie. Six authors declared being current or former employees or stockholders of AbbVie. The other authors reported ties with several sources, including AbbVie.

Source: McInnes IB et al. Efficacy and safety of upadacitinib in patients with psoriatic arthritis: 2-year results from the phase 3 SELECT-PsA 1 study. Rheumatol Ther. 2022 (Oct 15). Doi: 10.1007/s40744-022-00499-w

Key clinical point: Compared with adalimumab, both 15 mg and 30 mg upadacitinib showed similar or better efficacy through 2 years and a similar safety profile in patients with psoriatic arthritis (PsA).

Major finding: At week 104, a similar proportion of patients receiving 15/30 mg upadacitinib vs adalimumab achieved ≥20% improvement in the American College of Rheumatology criteria (69.0%/69.5% vs 63.4%), whereas significantly more patients receiving 30 mg upadacitinib vs adalimumab achieved minimal disease activity (45.9% vs 37.8%; P < .05). The safety profiles of upadacitinib and adalimumab were comparable.

Study details: Findings are from an exploratory analysis of the SELECT-PsA 1 study including 1704 patients with active PsA and inadequate response/intolerance to ≥1 non-biologic disease-modifying antirheumatic drug who were randomly assigned to receive upadacitinib (15 or 30 mg) or adalimumab.

Disclosures: This study was funded by AbbVie. Six authors declared being current or former employees or stockholders of AbbVie. The other authors reported ties with several sources, including AbbVie.

Source: McInnes IB et al. Efficacy and safety of upadacitinib in patients with psoriatic arthritis: 2-year results from the phase 3 SELECT-PsA 1 study. Rheumatol Ther. 2022 (Oct 15). Doi: 10.1007/s40744-022-00499-w

Key clinical point: Compared with adalimumab, both 15 mg and 30 mg upadacitinib showed similar or better efficacy through 2 years and a similar safety profile in patients with psoriatic arthritis (PsA).

Major finding: At week 104, a similar proportion of patients receiving 15/30 mg upadacitinib vs adalimumab achieved ≥20% improvement in the American College of Rheumatology criteria (69.0%/69.5% vs 63.4%), whereas significantly more patients receiving 30 mg upadacitinib vs adalimumab achieved minimal disease activity (45.9% vs 37.8%; P < .05). The safety profiles of upadacitinib and adalimumab were comparable.

Study details: Findings are from an exploratory analysis of the SELECT-PsA 1 study including 1704 patients with active PsA and inadequate response/intolerance to ≥1 non-biologic disease-modifying antirheumatic drug who were randomly assigned to receive upadacitinib (15 or 30 mg) or adalimumab.

Disclosures: This study was funded by AbbVie. Six authors declared being current or former employees or stockholders of AbbVie. The other authors reported ties with several sources, including AbbVie.

Source: McInnes IB et al. Efficacy and safety of upadacitinib in patients with psoriatic arthritis: 2-year results from the phase 3 SELECT-PsA 1 study. Rheumatol Ther. 2022 (Oct 15). Doi: 10.1007/s40744-022-00499-w

Key clinical point: Singleton pregnant women with psoriatic arthritis (PsA) had a significantly higher risk for preeclampsia than matched control pregnant women without PsA.

Major finding: Compared with control women, the risk for preeclampsia was much higher in women with PsA (adjusted odds ratio [aOR] 1.85; 95% CI 1.10-3.12), with the risk being primarily driven by the receipt of monotherapy for PsA before pregnancy (aOR 2.72; 95% CI 1.44-5.13).

Study details: Findings are from an analysis of a register-based cohort study including singleton pregnant women with rheumatoid arthritis (n = 1739), axial spondyloarthritis (n = 819), and PsA (n = 489) who were matched with 17,390, 8190, and 4890 control pregnant women, respectively.

Disclosures: This study was supported by NordForsk and other sources. Some authors declared serving on speakers’ bureaus, receiving research grants, or receiving  consulting fees from several sources.

Source: Secher AEP et al. Risk of pre-eclampsia and impact of disease activity and antirheumatic treatment in women with rheumatoid arthritis, axial spondylarthritis and psoriatic arthritis: A collaborative matched cohort study from Sweden and Denmark. RMD Open. 2022;8:e002445 (Nov 3). Doi: 10.1136/rmdopen-2022-002445

Key clinical point: Singleton pregnant women with psoriatic arthritis (PsA) had a significantly higher risk for preeclampsia than matched control pregnant women without PsA.

Major finding: Compared with control women, the risk for preeclampsia was much higher in women with PsA (adjusted odds ratio [aOR] 1.85; 95% CI 1.10-3.12), with the risk being primarily driven by the receipt of monotherapy for PsA before pregnancy (aOR 2.72; 95% CI 1.44-5.13).

Study details: Findings are from an analysis of a register-based cohort study including singleton pregnant women with rheumatoid arthritis (n = 1739), axial spondyloarthritis (n = 819), and PsA (n = 489) who were matched with 17,390, 8190, and 4890 control pregnant women, respectively.

Disclosures: This study was supported by NordForsk and other sources. Some authors declared serving on speakers’ bureaus, receiving research grants, or receiving  consulting fees from several sources.

Source: Secher AEP et al. Risk of pre-eclampsia and impact of disease activity and antirheumatic treatment in women with rheumatoid arthritis, axial spondylarthritis and psoriatic arthritis: A collaborative matched cohort study from Sweden and Denmark. RMD Open. 2022;8:e002445 (Nov 3). Doi: 10.1136/rmdopen-2022-002445

Key clinical point: Singleton pregnant women with psoriatic arthritis (PsA) had a significantly higher risk for preeclampsia than matched control pregnant women without PsA.

Major finding: Compared with control women, the risk for preeclampsia was much higher in women with PsA (adjusted odds ratio [aOR] 1.85; 95% CI 1.10-3.12), with the risk being primarily driven by the receipt of monotherapy for PsA before pregnancy (aOR 2.72; 95% CI 1.44-5.13).

Study details: Findings are from an analysis of a register-based cohort study including singleton pregnant women with rheumatoid arthritis (n = 1739), axial spondyloarthritis (n = 819), and PsA (n = 489) who were matched with 17,390, 8190, and 4890 control pregnant women, respectively.

Disclosures: This study was supported by NordForsk and other sources. Some authors declared serving on speakers’ bureaus, receiving research grants, or receiving  consulting fees from several sources.

Source: Secher AEP et al. Risk of pre-eclampsia and impact of disease activity and antirheumatic treatment in women with rheumatoid arthritis, axial spondylarthritis and psoriatic arthritis: A collaborative matched cohort study from Sweden and Denmark. RMD Open. 2022;8:e002445 (Nov 3). Doi: 10.1136/rmdopen-2022-002445

Key clinical point: Risankizumab demonstrated long-term (52 weeks) efficacy in reducing disease severity and showed a consistent safety profile in patients with psoriatic arthritis (PsA) and previous inadequate response or intolerance to ≥1 conventional synthetic disease-modifying antirheumatic drug (csDMARD-IR).

Major finding: Among patients who received risankizumab continuously, those achieving ≥20% improvement in American College of Rheumatology (ACR20) response increased from 57.3% at week 24 to 70.0% at week 52; meanwhile, 63.0% of patients who switched from placebo to risankizumab achieved ACR20 at week 52. No new safety signals were identified.

Study details: Findings are from the ongoing phase 3 KEEPsAKE 1 study including 964 patients with active PsA who were csDMARD-IR and were randomly assigned to receive risankizumab or placebo for 24 weeks, of which 940 patients were eligible to receive open-label risankizumab through 208 weeks.

Disclosures: This study was funded by AbbVie. Four authors declared being employees or holding stock options in AbbVie, and the other authors reported ties with several sources, including AbbVie.

Source: Kristensen LE et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study. Rheumatology (Oxford). 2022 (Oct 25). Doi: 10.1093/rheumatology/keac607

Key clinical point: Risankizumab demonstrated long-term (52 weeks) efficacy in reducing disease severity and showed a consistent safety profile in patients with psoriatic arthritis (PsA) and previous inadequate response or intolerance to ≥1 conventional synthetic disease-modifying antirheumatic drug (csDMARD-IR).

Major finding: Among patients who received risankizumab continuously, those achieving ≥20% improvement in American College of Rheumatology (ACR20) response increased from 57.3% at week 24 to 70.0% at week 52; meanwhile, 63.0% of patients who switched from placebo to risankizumab achieved ACR20 at week 52. No new safety signals were identified.

Study details: Findings are from the ongoing phase 3 KEEPsAKE 1 study including 964 patients with active PsA who were csDMARD-IR and were randomly assigned to receive risankizumab or placebo for 24 weeks, of which 940 patients were eligible to receive open-label risankizumab through 208 weeks.

Disclosures: This study was funded by AbbVie. Four authors declared being employees or holding stock options in AbbVie, and the other authors reported ties with several sources, including AbbVie.

Source: Kristensen LE et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study. Rheumatology (Oxford). 2022 (Oct 25). Doi: 10.1093/rheumatology/keac607

Key clinical point: Risankizumab demonstrated long-term (52 weeks) efficacy in reducing disease severity and showed a consistent safety profile in patients with psoriatic arthritis (PsA) and previous inadequate response or intolerance to ≥1 conventional synthetic disease-modifying antirheumatic drug (csDMARD-IR).

Major finding: Among patients who received risankizumab continuously, those achieving ≥20% improvement in American College of Rheumatology (ACR20) response increased from 57.3% at week 24 to 70.0% at week 52; meanwhile, 63.0% of patients who switched from placebo to risankizumab achieved ACR20 at week 52. No new safety signals were identified.

Study details: Findings are from the ongoing phase 3 KEEPsAKE 1 study including 964 patients with active PsA who were csDMARD-IR and were randomly assigned to receive risankizumab or placebo for 24 weeks, of which 940 patients were eligible to receive open-label risankizumab through 208 weeks.

Disclosures: This study was funded by AbbVie. Four authors declared being employees or holding stock options in AbbVie, and the other authors reported ties with several sources, including AbbVie.

Source: Kristensen LE et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study. Rheumatology (Oxford). 2022 (Oct 25). Doi: 10.1093/rheumatology/keac607

Key clinical point: Once-monthly galcanezumab significantly reduced the frequency of migraine-associated symptoms and migraine headache severity in patients with episodic migraine.

Major finding: Moderate-to-severe migraine headache days (MHD) reduced significantly with 240 mg galcanezumab (difference in least-squares mean change from baseline [Δ] −1.8 days,  95% CI −2.5 to −1.2) and 120 mg (Δ −1.9 days, 95% CI −2.5 to −1.2) vs placebo, with 240 mg galcanezumab also leading to significant reductions in the proportion of monthly MHD during menstrual periods (P = .04), and MHDswith nausea or vomiting (P = .02).

Study details: This was a secondary analysis of a phase 2 trial including 440 patients with episodic migraine who were randomly assigned to receive monthly galcanezumab (240 or 120 mg) or placebo.

Disclosures: This study was funded by Eli Lilly Japan K.K. Two authors declared being employees and minor shareholders of Eli Lilly. Two authors reported receiving personal fees for speaker or consulting services from Eli Lilly Japan K.K. and other sources.

Source: Igarashi H et al. Galcanezumab effects on migraine severity and symptoms in Japanese patients with episodic migraine: Secondary analysis of a phase 2 randomized trial. Neurol Ther. 2022 (Oct 20). Doi: 10.1007/s40120-022-00410-3

Key clinical point: Once-monthly galcanezumab significantly reduced the frequency of migraine-associated symptoms and migraine headache severity in patients with episodic migraine.

Major finding: Moderate-to-severe migraine headache days (MHD) reduced significantly with 240 mg galcanezumab (difference in least-squares mean change from baseline [Δ] −1.8 days,  95% CI −2.5 to −1.2) and 120 mg (Δ −1.9 days, 95% CI −2.5 to −1.2) vs placebo, with 240 mg galcanezumab also leading to significant reductions in the proportion of monthly MHD during menstrual periods (P = .04), and MHDswith nausea or vomiting (P = .02).

Study details: This was a secondary analysis of a phase 2 trial including 440 patients with episodic migraine who were randomly assigned to receive monthly galcanezumab (240 or 120 mg) or placebo.

Disclosures: This study was funded by Eli Lilly Japan K.K. Two authors declared being employees and minor shareholders of Eli Lilly. Two authors reported receiving personal fees for speaker or consulting services from Eli Lilly Japan K.K. and other sources.

Source: Igarashi H et al. Galcanezumab effects on migraine severity and symptoms in Japanese patients with episodic migraine: Secondary analysis of a phase 2 randomized trial. Neurol Ther. 2022 (Oct 20). Doi: 10.1007/s40120-022-00410-3

Key clinical point: Once-monthly galcanezumab significantly reduced the frequency of migraine-associated symptoms and migraine headache severity in patients with episodic migraine.

Major finding: Moderate-to-severe migraine headache days (MHD) reduced significantly with 240 mg galcanezumab (difference in least-squares mean change from baseline [Δ] −1.8 days,  95% CI −2.5 to −1.2) and 120 mg (Δ −1.9 days, 95% CI −2.5 to −1.2) vs placebo, with 240 mg galcanezumab also leading to significant reductions in the proportion of monthly MHD during menstrual periods (P = .04), and MHDswith nausea or vomiting (P = .02).

Study details: This was a secondary analysis of a phase 2 trial including 440 patients with episodic migraine who were randomly assigned to receive monthly galcanezumab (240 or 120 mg) or placebo.

Disclosures: This study was funded by Eli Lilly Japan K.K. Two authors declared being employees and minor shareholders of Eli Lilly. Two authors reported receiving personal fees for speaker or consulting services from Eli Lilly Japan K.K. and other sources.

Source: Igarashi H et al. Galcanezumab effects on migraine severity and symptoms in Japanese patients with episodic migraine: Secondary analysis of a phase 2 randomized trial. Neurol Ther. 2022 (Oct 20). Doi: 10.1007/s40120-022-00410-3

Key clinical point: Adenosine vs placebo infusion increased headaches and short-lasting vasodilation without a significant induction of migraine attacks in patients with migraine without aura.

Major finding: The incidence of migraine attacks was not significantly different after adenosine vs placebo infusion (39% vs 17%; P = .29); however, a higher proportion of patients receiving adenosine vs placebo reported headache (78% vs 33%; P < .01). Adenosine vs placebo increased heart rate (area under the curve [AUC]_{T0-120 min}, P < .001), facial skin blood flow (AUC_{T0-120 min}, P < .05), and left superficial temporal artery diameter (AUC_{T0-20 min}, P = .01), but decreased middle cerebral artery blood flow velocity (AUC_{T0-20 min}, P < .001).

Study details: This randomized controlled trial included 18 patients with migraine without aura who received adenosine or placebo infusion over 20 minutes on two study days separated by a 1 week washout period.

Disclosures: This study received support from the Lundbeck Foundation. M Ashina reported receiving consulting fees, honoraria for lectures and presentations, and royalties from various sources, including Lundbeck.

Source: Thuraiaiyah J et al. Adenosine causes short-lasting vasodilation and headache, but not migraine attacks in migraine patients: A randomized clinical trial. Pain. 2022 (Oct 17). Doi: 10.1097/j.pain.0000000000002804

Key clinical point: Adenosine vs placebo infusion increased headaches and short-lasting vasodilation without a significant induction of migraine attacks in patients with migraine without aura.

Major finding: The incidence of migraine attacks was not significantly different after adenosine vs placebo infusion (39% vs 17%; P = .29); however, a higher proportion of patients receiving adenosine vs placebo reported headache (78% vs 33%; P < .01). Adenosine vs placebo increased heart rate (area under the curve [AUC]_{T0-120 min}, P < .001), facial skin blood flow (AUC_{T0-120 min}, P < .05), and left superficial temporal artery diameter (AUC_{T0-20 min}, P = .01), but decreased middle cerebral artery blood flow velocity (AUC_{T0-20 min}, P < .001).

Study details: This randomized controlled trial included 18 patients with migraine without aura who received adenosine or placebo infusion over 20 minutes on two study days separated by a 1 week washout period.

Disclosures: This study received support from the Lundbeck Foundation. M Ashina reported receiving consulting fees, honoraria for lectures and presentations, and royalties from various sources, including Lundbeck.

Source: Thuraiaiyah J et al. Adenosine causes short-lasting vasodilation and headache, but not migraine attacks in migraine patients: A randomized clinical trial. Pain. 2022 (Oct 17). Doi: 10.1097/j.pain.0000000000002804

Key clinical point: Adenosine vs placebo infusion increased headaches and short-lasting vasodilation without a significant induction of migraine attacks in patients with migraine without aura.

Major finding: The incidence of migraine attacks was not significantly different after adenosine vs placebo infusion (39% vs 17%; P = .29); however, a higher proportion of patients receiving adenosine vs placebo reported headache (78% vs 33%; P < .01). Adenosine vs placebo increased heart rate (area under the curve [AUC]_{T0-120 min}, P < .001), facial skin blood flow (AUC_{T0-120 min}, P < .05), and left superficial temporal artery diameter (AUC_{T0-20 min}, P = .01), but decreased middle cerebral artery blood flow velocity (AUC_{T0-20 min}, P < .001).

Study details: This randomized controlled trial included 18 patients with migraine without aura who received adenosine or placebo infusion over 20 minutes on two study days separated by a 1 week washout period.

Disclosures: This study received support from the Lundbeck Foundation. M Ashina reported receiving consulting fees, honoraria for lectures and presentations, and royalties from various sources, including Lundbeck.

Source: Thuraiaiyah J et al. Adenosine causes short-lasting vasodilation and headache, but not migraine attacks in migraine patients: A randomized clinical trial. Pain. 2022 (Oct 17). Doi: 10.1097/j.pain.0000000000002804

Key clinical point: Individuals diagnosed with childhood cancer were at an increased risk for antimigraine medication and hospitalization due to migraine.

Major finding: Compared with unaffected individuals, those diagnosed with childhood cancer were at an elevated risk for initiating antimigraine therapy (standardized incidence ratios [SIR] 1.22; 95% CI 1.09-1.36) and hospitalization due to migraine (SIR 2.44; 95% CI 1.87-3.12), with the risk for initiating antimigraine therapy being the highest among individuals diagnosed with cancer at 15-19 years of age (SIR 1.48; 95% CI 1.25-1.74).

Study details: This was a population-based cohort study including individuals diagnosed with childhood cancer who had data available for antimigraine prescriptions (n = 6564) and migraine hospitalization (n = 7771).

Disclosures: This study was funded by Danmarks Frie Forskningsfond, Denmark. The authors declared no conflicts of interest.

Source: Davidsson OB et al. Childhood cancer confers increased risk of migraine – A Danish nationwide register study. Cancer Epidemiol. 2022;81:102278 (Oct 13). Doi: 10.1016/j.canep.2022.102278

Key clinical point: Individuals diagnosed with childhood cancer were at an increased risk for antimigraine medication and hospitalization due to migraine.

Major finding: Compared with unaffected individuals, those diagnosed with childhood cancer were at an elevated risk for initiating antimigraine therapy (standardized incidence ratios [SIR] 1.22; 95% CI 1.09-1.36) and hospitalization due to migraine (SIR 2.44; 95% CI 1.87-3.12), with the risk for initiating antimigraine therapy being the highest among individuals diagnosed with cancer at 15-19 years of age (SIR 1.48; 95% CI 1.25-1.74).

Study details: This was a population-based cohort study including individuals diagnosed with childhood cancer who had data available for antimigraine prescriptions (n = 6564) and migraine hospitalization (n = 7771).

Disclosures: This study was funded by Danmarks Frie Forskningsfond, Denmark. The authors declared no conflicts of interest.

Source: Davidsson OB et al. Childhood cancer confers increased risk of migraine – A Danish nationwide register study. Cancer Epidemiol. 2022;81:102278 (Oct 13). Doi: 10.1016/j.canep.2022.102278

Key clinical point: Individuals diagnosed with childhood cancer were at an increased risk for antimigraine medication and hospitalization due to migraine.

Major finding: Compared with unaffected individuals, those diagnosed with childhood cancer were at an elevated risk for initiating antimigraine therapy (standardized incidence ratios [SIR] 1.22; 95% CI 1.09-1.36) and hospitalization due to migraine (SIR 2.44; 95% CI 1.87-3.12), with the risk for initiating antimigraine therapy being the highest among individuals diagnosed with cancer at 15-19 years of age (SIR 1.48; 95% CI 1.25-1.74).

Study details: This was a population-based cohort study including individuals diagnosed with childhood cancer who had data available for antimigraine prescriptions (n = 6564) and migraine hospitalization (n = 7771).

Disclosures: This study was funded by Danmarks Frie Forskningsfond, Denmark. The authors declared no conflicts of interest.

Source: Davidsson OB et al. Childhood cancer confers increased risk of migraine – A Danish nationwide register study. Cancer Epidemiol. 2022;81:102278 (Oct 13). Doi: 10.1016/j.canep.2022.102278

Key clinical point: The presence of seemingly inert calcified lesions of neurocysticercosis (CLN) influences the course of migraine by increasing headache frequency, pain severity, and migraine-associated disability; however, patients with CLN showed a better response to amitriptyline treatment.

Major finding: In patients with vs without CLN, the headache frequency (P < .001), visual analog scale score (P < .001), and Migraine Disability Assessment score (P < .001) were significantly higher at baseline and not significantly different at 3 months after amitriptyline treatment; however, the magnitude of treatment response was significantly higher in patients with vs without CLN (P < .001).

Study details: This case-control study included age- and sex-matched patients with migraine with (n = 78) and without (n = 78) CLN on cranial computed tomography who received preventive treatment with amitriptyline.

Disclosures: The publication expenses were supported by the American Society of Tropical Medicine and Hygiene. RK Garg reported receiving royalties for writing UpToDate articles and an honorarium for writing for MedLink Neurology.

Source: Sharma K et al. Does calcified neurocysticercosis affect migraine characteristics and treatment responsiveness? A case-control study. Am J Trop Med Hyg. 2022 (Oct 10). Doi: 10.4269/ajtmh.22-0335

Key clinical point: The presence of seemingly inert calcified lesions of neurocysticercosis (CLN) influences the course of migraine by increasing headache frequency, pain severity, and migraine-associated disability; however, patients with CLN showed a better response to amitriptyline treatment.

Major finding: In patients with vs without CLN, the headache frequency (P < .001), visual analog scale score (P < .001), and Migraine Disability Assessment score (P < .001) were significantly higher at baseline and not significantly different at 3 months after amitriptyline treatment; however, the magnitude of treatment response was significantly higher in patients with vs without CLN (P < .001).

Study details: This case-control study included age- and sex-matched patients with migraine with (n = 78) and without (n = 78) CLN on cranial computed tomography who received preventive treatment with amitriptyline.

Disclosures: The publication expenses were supported by the American Society of Tropical Medicine and Hygiene. RK Garg reported receiving royalties for writing UpToDate articles and an honorarium for writing for MedLink Neurology.

Source: Sharma K et al. Does calcified neurocysticercosis affect migraine characteristics and treatment responsiveness? A case-control study. Am J Trop Med Hyg. 2022 (Oct 10). Doi: 10.4269/ajtmh.22-0335

Key clinical point: The presence of seemingly inert calcified lesions of neurocysticercosis (CLN) influences the course of migraine by increasing headache frequency, pain severity, and migraine-associated disability; however, patients with CLN showed a better response to amitriptyline treatment.

Major finding: In patients with vs without CLN, the headache frequency (P < .001), visual analog scale score (P < .001), and Migraine Disability Assessment score (P < .001) were significantly higher at baseline and not significantly different at 3 months after amitriptyline treatment; however, the magnitude of treatment response was significantly higher in patients with vs without CLN (P < .001).

Study details: This case-control study included age- and sex-matched patients with migraine with (n = 78) and without (n = 78) CLN on cranial computed tomography who received preventive treatment with amitriptyline.

Disclosures: The publication expenses were supported by the American Society of Tropical Medicine and Hygiene. RK Garg reported receiving royalties for writing UpToDate articles and an honorarium for writing for MedLink Neurology.

Source: Sharma K et al. Does calcified neurocysticercosis affect migraine characteristics and treatment responsiveness? A case-control study. Am J Trop Med Hyg. 2022 (Oct 10). Doi: 10.4269/ajtmh.22-0335

Key clinical point: Autonomic symptoms were prevalent in patients with episodic or chronic migraine but demonstrated no significant correlation with headache frequency, treatment response, or reversion from chronic to episodic migraine.

Major finding: Overall, 60.5% of patients reported a Composite Autonomic Symptom Scale (COMPASS-31) score of ≥30. The median monthly headache days (P = .002) and Migraine Disability Assessment Score (P = .01) reduced significantly during the study period but change in the mean weighted COMPASS-31 score was not significant (P = .885), with no correlation observed between the COMPASS-31 score and monthly headache frequency or reversion from chronic to episodic migraine.

Study details: This was a prospective longitudinal cohort study including 43 patients with episodic or chronic migraine who completed 12 months of treatment and follow-up surveys.

Disclosures: This study did not report the source of funding. Four authors declared receiving funding, grants, or payment for developing educational presentations, serving on advisory boards, or being involved in clinical trials sponsored by various sources.

Source: Ray JC et al. Autonomic symptoms in migraine: Results of a prospective longitudinal study. Front Neurol. 2022;13:1036798 (Nov 3). Doi: 10.3389/fneur.2022.1036798

Key clinical point: Autonomic symptoms were prevalent in patients with episodic or chronic migraine but demonstrated no significant correlation with headache frequency, treatment response, or reversion from chronic to episodic migraine.

Major finding: Overall, 60.5% of patients reported a Composite Autonomic Symptom Scale (COMPASS-31) score of ≥30. The median monthly headache days (P = .002) and Migraine Disability Assessment Score (P = .01) reduced significantly during the study period but change in the mean weighted COMPASS-31 score was not significant (P = .885), with no correlation observed between the COMPASS-31 score and monthly headache frequency or reversion from chronic to episodic migraine.

Study details: This was a prospective longitudinal cohort study including 43 patients with episodic or chronic migraine who completed 12 months of treatment and follow-up surveys.

Disclosures: This study did not report the source of funding. Four authors declared receiving funding, grants, or payment for developing educational presentations, serving on advisory boards, or being involved in clinical trials sponsored by various sources.

Source: Ray JC et al. Autonomic symptoms in migraine: Results of a prospective longitudinal study. Front Neurol. 2022;13:1036798 (Nov 3). Doi: 10.3389/fneur.2022.1036798

Key clinical point: Autonomic symptoms were prevalent in patients with episodic or chronic migraine but demonstrated no significant correlation with headache frequency, treatment response, or reversion from chronic to episodic migraine.

Major finding: Overall, 60.5% of patients reported a Composite Autonomic Symptom Scale (COMPASS-31) score of ≥30. The median monthly headache days (P = .002) and Migraine Disability Assessment Score (P = .01) reduced significantly during the study period but change in the mean weighted COMPASS-31 score was not significant (P = .885), with no correlation observed between the COMPASS-31 score and monthly headache frequency or reversion from chronic to episodic migraine.

Study details: This was a prospective longitudinal cohort study including 43 patients with episodic or chronic migraine who completed 12 months of treatment and follow-up surveys.

Disclosures: This study did not report the source of funding. Four authors declared receiving funding, grants, or payment for developing educational presentations, serving on advisory boards, or being involved in clinical trials sponsored by various sources.

Source: Ray JC et al. Autonomic symptoms in migraine: Results of a prospective longitudinal study. Front Neurol. 2022;13:1036798 (Nov 3). Doi: 10.3389/fneur.2022.1036798

Key clinical point: During acute headaches, patients with migraine had elevated levels of peripheral inflammatory markers (PIM), specifically the neutrophil-to-lymphocyte ratio (NLR) and the neutrophil-to-monocyte ratio (NMR), which could fairly differentiate between the migraine and no headache groups.

Major finding: Patients with migraine had higher NLR, NMR, and monocyte-to-lymphocyte ratio (all P < .001) compared with control individuals without headache and higher NMR (P < .001) and higher NLR (P = .051) compared with patients with non-migraine headaches during acute headache attacks. NLR and NMR could fairly differentiate between the migraine and no headache groups (NLR: area under the curve [AUC] 0.65; NMR: AUC 0.61; P < .001).

Study details: This was a retrospective analysis of 4005 patients with acute headache attack, including those with migraine (n = 1453) or non-migraine (n = 2552) headaches, and 88,586 control individuals without headache.

Disclosures: This study was supported by Basic Science Research Program through the National Research Foundataion of Korea funded by the Ministry of Education and others. The authors declared no conflicts of interest.

Source: Lee S-H et al. Role of peripheral inflammatory markers in patients with acute headache attack to differentiate between migraine and non-migraine headache. J Clin Med. 2022;11(21):6538 (Nov 3). Doi: 10.3390/jcm11216538

Key clinical point: During acute headaches, patients with migraine had elevated levels of peripheral inflammatory markers (PIM), specifically the neutrophil-to-lymphocyte ratio (NLR) and the neutrophil-to-monocyte ratio (NMR), which could fairly differentiate between the migraine and no headache groups.

Major finding: Patients with migraine had higher NLR, NMR, and monocyte-to-lymphocyte ratio (all P < .001) compared with control individuals without headache and higher NMR (P < .001) and higher NLR (P = .051) compared with patients with non-migraine headaches during acute headache attacks. NLR and NMR could fairly differentiate between the migraine and no headache groups (NLR: area under the curve [AUC] 0.65; NMR: AUC 0.61; P < .001).

Study details: This was a retrospective analysis of 4005 patients with acute headache attack, including those with migraine (n = 1453) or non-migraine (n = 2552) headaches, and 88,586 control individuals without headache.

Disclosures: This study was supported by Basic Science Research Program through the National Research Foundataion of Korea funded by the Ministry of Education and others. The authors declared no conflicts of interest.

Source: Lee S-H et al. Role of peripheral inflammatory markers in patients with acute headache attack to differentiate between migraine and non-migraine headache. J Clin Med. 2022;11(21):6538 (Nov 3). Doi: 10.3390/jcm11216538

Key clinical point: During acute headaches, patients with migraine had elevated levels of peripheral inflammatory markers (PIM), specifically the neutrophil-to-lymphocyte ratio (NLR) and the neutrophil-to-monocyte ratio (NMR), which could fairly differentiate between the migraine and no headache groups.

Major finding: Patients with migraine had higher NLR, NMR, and monocyte-to-lymphocyte ratio (all P < .001) compared with control individuals without headache and higher NMR (P < .001) and higher NLR (P = .051) compared with patients with non-migraine headaches during acute headache attacks. NLR and NMR could fairly differentiate between the migraine and no headache groups (NLR: area under the curve [AUC] 0.65; NMR: AUC 0.61; P < .001).

Study details: This was a retrospective analysis of 4005 patients with acute headache attack, including those with migraine (n = 1453) or non-migraine (n = 2552) headaches, and 88,586 control individuals without headache.

Disclosures: This study was supported by Basic Science Research Program through the National Research Foundataion of Korea funded by the Ministry of Education and others. The authors declared no conflicts of interest.

Source: Lee S-H et al. Role of peripheral inflammatory markers in patients with acute headache attack to differentiate between migraine and non-migraine headache. J Clin Med. 2022;11(21):6538 (Nov 3). Doi: 10.3390/jcm11216538

Key clinical point: Migraine pain characteristics indicating peripheral or central sensitization may help predict ≥50% response to anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibodies (mAb) in patients with high frequency episodic migraine (HFEM) or chronic migraine (CM).

Major finding: In HFEM, unilateral pain (UP) + unilateral cranial autonomic symptoms (UA) positively predicted ≥50% response (odds ratio [OR] 4.23; P = .004), whereas in CM, UP (OR 1.46; P = .039), UA (OR 1.49; P = .026), UP+UA (OR 1.90; P = .012), and UP+allodynia (OR 1.71; P = .034) positively predicted ≥50% response and obesity negatively predicted ≥50% response (OR 0.21; P = .006).

Study details: This was a real-life prospective cohort study including 864 anti-CGRP mAb-naive patients with HFEM or CM and unresponsiveness or contraindications for or low tolerability to >3 migraine preventive medications, who were prescribed erenumab, galcanezumab, or fremanezumab for ≥24 weeks.

Disclosures: This study was partially supported by the Italian Ministry of Health IRCCS San Raffaele Roma. Several authors reported receiving personal compensation, travel grants, honoraria, or research support from various sources.

Source: Barbanti P et al. Predictors of response to anti-CGRP monoclonal antibodies: A 24-week, multicenter, prospective study on 864 migraine patients. J Headache Pain. 2022;23:138 (Nov 1). Doi: 10.1186/s10194-022-01498-6

Key clinical point: Migraine pain characteristics indicating peripheral or central sensitization may help predict ≥50% response to anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibodies (mAb) in patients with high frequency episodic migraine (HFEM) or chronic migraine (CM).

Major finding: In HFEM, unilateral pain (UP) + unilateral cranial autonomic symptoms (UA) positively predicted ≥50% response (odds ratio [OR] 4.23; P = .004), whereas in CM, UP (OR 1.46; P = .039), UA (OR 1.49; P = .026), UP+UA (OR 1.90; P = .012), and UP+allodynia (OR 1.71; P = .034) positively predicted ≥50% response and obesity negatively predicted ≥50% response (OR 0.21; P = .006).

Study details: This was a real-life prospective cohort study including 864 anti-CGRP mAb-naive patients with HFEM or CM and unresponsiveness or contraindications for or low tolerability to >3 migraine preventive medications, who were prescribed erenumab, galcanezumab, or fremanezumab for ≥24 weeks.

Disclosures: This study was partially supported by the Italian Ministry of Health IRCCS San Raffaele Roma. Several authors reported receiving personal compensation, travel grants, honoraria, or research support from various sources.

Source: Barbanti P et al. Predictors of response to anti-CGRP monoclonal antibodies: A 24-week, multicenter, prospective study on 864 migraine patients. J Headache Pain. 2022;23:138 (Nov 1). Doi: 10.1186/s10194-022-01498-6

Key clinical point: Migraine pain characteristics indicating peripheral or central sensitization may help predict ≥50% response to anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibodies (mAb) in patients with high frequency episodic migraine (HFEM) or chronic migraine (CM).

Major finding: In HFEM, unilateral pain (UP) + unilateral cranial autonomic symptoms (UA) positively predicted ≥50% response (odds ratio [OR] 4.23; P = .004), whereas in CM, UP (OR 1.46; P = .039), UA (OR 1.49; P = .026), UP+UA (OR 1.90; P = .012), and UP+allodynia (OR 1.71; P = .034) positively predicted ≥50% response and obesity negatively predicted ≥50% response (OR 0.21; P = .006).

Study details: This was a real-life prospective cohort study including 864 anti-CGRP mAb-naive patients with HFEM or CM and unresponsiveness or contraindications for or low tolerability to >3 migraine preventive medications, who were prescribed erenumab, galcanezumab, or fremanezumab for ≥24 weeks.

Disclosures: This study was partially supported by the Italian Ministry of Health IRCCS San Raffaele Roma. Several authors reported receiving personal compensation, travel grants, honoraria, or research support from various sources.

Source: Barbanti P et al. Predictors of response to anti-CGRP monoclonal antibodies: A 24-week, multicenter, prospective study on 864 migraine patients. J Headache Pain. 2022;23:138 (Nov 1). Doi: 10.1186/s10194-022-01498-6